Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Haferlach

Showing results (251-260 of 596) with videos related to

Pageof 60
Sort By:
Leukemia|June 20, 2022
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogeneticsIrene Fuhrmann, Miriam Lenk, Torsten Haferlach, et al.
Annals of Hematology|September 10, 2015
Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AMLAnnette Fasan, Claudia Haferlach, Christiane Eder, et al.
Leukemia|February 22, 2023
MDS subclassification-do we still have to count blasts?Sandra Huber, Torsten Haferlach, Heiko Müller, et al.
Blood Advances|July 28, 2023
Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDSAnna Stengel, Manja Meggendorfer, Wencke Walter, et al.
Leukemia|November 14, 2019
Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemiaLuise Hartmann, Niroshan Nadarajah, Manja Meggendorfer, et al.
Blood|February 15, 2012
Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemiaSusanne Schnittger, Ulrike Bacher, Torsten Haferlach, et al.
Haematologica|August 11, 2011
Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemiaVera Grossmann, Wolfgang Kern, Stefan Harbich, et al.
British Journal of Haematology|October 25, 2011
TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining alleleUlrike Bacher, Sandra Weissmann, Alexander Kohlmann, et al.
Genes, Chromosomes & Cancer|August 14, 2012
Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia casesClaudia Haferlach, Ulrike Bacher, Vera Grossmann, et al.
Haematologica|September 28, 2014
Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemiaSimone Thomas, Roland Schelker, Sebastian Klobuch, et al.
Pageof 60

Showing results (251-260 of 596) with videos related to

Sort By:
Pageof 60
Leukemia|June 20, 2022
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogeneticsIrene Fuhrmann, Miriam Lenk, Torsten Haferlach, et al.
Annals of Hematology|September 10, 2015
Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AMLAnnette Fasan, Claudia Haferlach, Christiane Eder, et al.
Leukemia|February 22, 2023
MDS subclassification-do we still have to count blasts?Sandra Huber, Torsten Haferlach, Heiko Müller, et al.
Blood Advances|July 28, 2023
Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDSAnna Stengel, Manja Meggendorfer, Wencke Walter, et al.
Leukemia|November 14, 2019
Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemiaLuise Hartmann, Niroshan Nadarajah, Manja Meggendorfer, et al.
Blood|February 15, 2012
Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemiaSusanne Schnittger, Ulrike Bacher, Torsten Haferlach, et al.
Haematologica|August 11, 2011
Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemiaVera Grossmann, Wolfgang Kern, Stefan Harbich, et al.
British Journal of Haematology|October 25, 2011
TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining alleleUlrike Bacher, Sandra Weissmann, Alexander Kohlmann, et al.
Genes, Chromosomes & Cancer|August 14, 2012
Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia casesClaudia Haferlach, Ulrike Bacher, Vera Grossmann, et al.
Haematologica|September 28, 2014
Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemiaSimone Thomas, Roland Schelker, Sebastian Klobuch, et al.
Pageof 60